Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can ...

Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.

Breelyn Wilky, MD, discusses what precision oncology advancements will most impact gastrointestinal stromal tumor management in the next 3 to 5 years.

Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

A paper in the British Journal of Surgery indicates that early-onset gastrointestinal cancer rates are rising dramatically ...

A phase 2 AXAGIST trial finds that avelumab combined with axitinib achieves durable disease control in patients with advanced gastrointestinal stromal tumours.

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, targeted therapies, and surgery techniques.

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) ...

Medically reviewed by Sohaib Imtiaz, MD Treatment for upper gastrointestinal (GI) cancers depends on several factors, including the type, location, and stage of the cancer (how far it has advanced).

Invikafusp alfa, a dual T-cell agonist targeting subsets of tumor-infiltrating lymphocytes, can elicit responses in patients with heavily pretreated gastrointestinal cancers, according to research ...